Aplantex develops a proprietary photosynthetic phytoreplicator platform — a plant-based biotechnology process the company says enables high-value production with a lower environmental footprint. The company is moving from a research-focused stage toward scalable, production-oriented operations, including adding an industrial-grade pilot plant at its innovation center. Aplantex reports ongoing R&D projects are on track to meet the needs of its existing national and international clients and is pursuing initiatives to improve process efficiency and reduce selection time for phytoreplicator variants. The company secured a $5 million bridge financing round in 2025 to support that operational transition and scale-up. Investissement Québec has been a principal partner in Aplantex's development and participated in the bridge round through its Impulsion Fund, while François Ravenelle led the financing.

Total raised

$9M

Funding rounds

5

Latest round

Equity

Latest activity

May 2026